Govt considers 10–20% temporary hike in essential medicine prices nationwide.
Pharma firms face rising input costs due to West Asia disruptions.
Relief likely time-bound with prices reverting after supply stabilises.
The government is thinking about raising the prices of essential medicines, like cancer drugs, by 10% to 20% for a short time to help pharmaceutical companies deal with higher input costs caused by supply problems in West Asia, according to Moneycontrol.
The proposal, which would put price controls on essential medicines like antibiotics, injectables, and cancer drugs, is being considered as a short-term solution, with a minimum time frame of three months being talked about.
1 April 2026
Get the latest issue of Outlook Business
“The government is inclined to help the industry overcome the current crisis but any increase will be limited to the duration of the disruption,” the source told Moneycontrol, indicating that the relief is likely to be time-bound.
Relief Likely to be Calibrated
Meanwhile some sections of the industry called for a hike of up to 50%, the government is unlikely to approve any across-the-board increase beyond a moderate range, the source said.
Prices are expected to revert to previous levels once supply conditions normalise.
The proposal has been backed by multiple industry bodies, including the Organisation of Pharmaceutical Producers of India (OPPI) and the Indian Pharmaceutical Alliance (IPA), along with individual companies.
As margins thin, drugmakers say that there is limited room to absorb further cost increases, cautioning that further price pressure could make the production of certain formulations unviable.
Price Relief Review
The proposal is being assessed as a temporary policy intervention to address cost pressures in the pharmaceutical sector arising from global supply chain disruptions, as reported by Moneycontrol.
Officials said that any support being considered would be very limited and only last for a short time. The goal would be to keep making important medicines without changing the long-term pricing structures. People in the industry are worried about shrinking margins and rising input volatility, especially in important therapeutic areas.
However, policymakers need to find a balance between making things affordable and making sure they can be made, so any changes should be small and short-lived. People are also talking about a framework that will include a way to reverse things once supply conditions are stable. This will make it more short-term and corrective, rather than a structural price change.
